Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates, omega-3 fatty acid compounds, and the novel proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, focus on improving lipid levels but ultimately aim to reduce the risk of CV events. Statins still dominate the market owing to their good risk-benefit profile and ability to reduce CVmorbidity and mortality. However, the evidence is not as strong for many of the nonstatin therapies. Using a longitudinal claims data analysis, we demonstrate how dyslipidemia is being treated in the United States and provide insight into what is driving current prescribing practices for newly diagnosed and recently treated patients.

QUESTIONS ANSWERED

  • What patient share do key therapies and brands garner by line of therapy in newly diagnosed dyslipidemia patients?
  • What are the quarterly trends in prescribing among recentlytreated and new diagnosed dyslipidemia patients?
  • How have PCSK9 inhibitors been integrated into the treatment algorithm?
  • What proportion of dyslipidemia patients receive drug therapy within one year of diagnosis, and how quickly?
  • What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of dyslipidemia patients are treated with monotherapy versus combination therapy?
  • What are the most widely used combination therapies?
  • What are the product-level compliance and persistency rates among drug-treated patients with dyslipidemia?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world, patient-level claims data, so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.

KEY DRUGS COVERED

Repatha, Praluent, Crestor, Zetia, Vytorin, Lovaza, Vascepa, statins, fibrates, omega-3 fatty acid compounds

KEY ANALYSIS PROVIDED

  • Brand useacross a longitudinal patient sample.
  • Newly diagnosed patient analysis.
  • Treatment initiation and progression.
  • Line of therapy analysis and combination therapy analysis.
  • Source of business for recently treated patients.
  • Persistency and compliance analysis.
  • Product-level patient flowcharts.

Related Reports

Dyslipidemia - Landscape & Forecast - Disease Landscape & Forecast

Dyslipidemia is a key modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). Current...

View Details

Dyslipidemia | Disease Landscape and Forecast | G7 | 2020

Dyslipidemia is a key modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). Current lipid-modifying therapies include statins, ezetimibe, fibrates, omega-3 fatty acid compounds...

View Details

Dyslipidemia - Epidemiology - Mature Markets

DRG Epidemiology’s coverage of dyslipidemia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dyslipidemia for each co...

View Details